サイト内検索


登録済み会員ログイン




未登録の方はこちらから登録できます。
新規会員登録


ご利用案内

ご利用案内


連絡先

TEL.03-5812-5270
FAX.03-3831-0495
E-mail:info@spi-information.com


関連サイト・サービス

市場調査のご依頼、専門分野のイベント・フォーラムの開催などは シード・プランニングにて承っております。

シードプランニング

世界の医療・医薬品産業レポートのデータベースサービスは、sekairyo.comにてご利用いただけます。

sekairyo.com

医療従事者へのあらゆる形態の調査は、メドサークルにお任せ下さい。

メドサークル


セキュリティについて

当サイトのコンテンツ利用時に送信される機密情報は、Verisign認証の元暗号化されて送信されます。


Hepatitis C: Drug Development Pipeline Study, H2 2018

C型肝炎:薬剤開発パイプライン調査2018年下半期

レポート概要

2020年までに推定市場価値300億ドルを超えるC型肝炎業界は、急成長する医療市場とみなされています。C型肝炎は世界中で約2億人の人々に影響を与え、治療失敗率は最も高くなっています。現在、HCVに対するワクチンはありません。C型肝炎ウイルスの突然変異のため、予防ワクチンの開発は非常に困難です。

同疾患は、6つの遺伝子型に分類され、そのうちGT-1遺伝子型が最も一般的です。また、急性または慢性のいずれかの感染性肝疾患です。肝硬変や肝臓癌をはじめとする肝臓の重大な問題に迅速に進行することがあります。

2018年6月現在、C型肝炎パイプラインには、85の薬剤が活発に開発されています。このうち、第1相は16剤、第2相は19剤で、第3相は4剤のみ、前臨床は27剤、研究/創薬は18剤でした。

60社がC型肝炎パイプライン治療薬を開発しており、このうちGinkgoPharma Co.、Biocad CJSC、Cocrystal Pharma Inc、ARA Healthcare Pvt Ltd、GlaxoSmithKline Pharmaceuticals Ltd、Beijing Kawin Technology Share-Holding Co.Ltd.、およびAchillion Pharmaceuticals Incがより多くの化合物を開発しています。一方、Presidio Pharmaceuticals、Inc.、F. Hoffmann-La Roche Ltd、Ascletis、Inc.およびBeijing Kawin Technology Share-Holding Co.,Ltd.は、最先端のパイプライン製品を保有しています。

ほとんどの治療候補の作用機序は、HCV NS5A阻害剤、免疫刺激剤および免疫調節剤です。

研究者、投資家、事業開発マネージャーを支援するため、VPA Research社はC型肝炎(HCV)パイプラインに関する包括的なレポートを作成しました。本レポートは、前臨床、研究、創薬、NDA / IND、申請中、第1相、第2相、および第3相試験における様々な治療候補についての洞察を提供します。単剤および併用療法のために開発された薬剤も含まれています。

HCV(C型肝炎)パイプライン製品ごとに、現在の状況、開発段階、参加企業および事業体、最近の開発、オーファンドラッグ/ファストトラック/その他の指定、薬剤クラスが提供されています。パイプライン製品の作用機序とターゲット領域も含まれます。さらに、臨床試験および前臨床試験ならびに治験結果も含まれています。

本レポートは、各製品の完全な詳細に加えて、C型肝炎(HCV)パイプライン研究の主要動向を明らかにします。開発中の製品は、開発中薬剤の種類と開発段階の詳細な洞察を提供するため、その開発段階、作用機序、および会社によって分類されます。

レポート詳細

目次

1 Table of Contents
1.1 LIST OF FIGURES
1.2 LIST OF TABLES

2 Executive Summary
2.1 DISEASE OVERVIEW
2.2 PIPELINE SNAPSHOT
2.3 PIPELINE DRUGS BY PHASE
2.4 PIPELINE DRUGS BY COMPANY
2.5 PIPELINE DRUGS BY MECHANISM OF ACTION

3 Hepatitis C- Company wise Pipeline Analysis
3.1 AKSHAYA BIO INC. PIPELINE, H1 2018
3.2 ALLACHEM, LLC PIPELINE, H1 2018
3.3 AMARNA THERAPEUTICS BV PIPELINE, H1 2018
3.4 ARA HEALTHCARE PVT LTD PIPELINE, H1 2018
3.5 ASCLETIS, INC PIPELINE, H1 2018
3.6 ATEA PHARMACEUTICALS, INC PIPELINE, H1 2018
3.7 BEIJING KAWIN TECHNOLOGY PIPELINE, H1 2018
3.8 BETA PHARMA, INC PIPELINE, H1 2018
3.9 BIOCAD CJSC PIPELINE, H1 2018
3.10 BIOTRON LIMITED PIPELINE, H1 2018
3.11 BOLDER BIOTECHNOLOGY, INC PIPELINE, H1 2018
3.12 ARTES BIOTECHNOLOGY GMBH PIPELINE, H1 2018
3.13 COCRYSTAL PHARMA INC PIPELINE, H1 2018
3.14 CONATUS PHARMACEUTICALS INC PIPELINE, H1 2018
3.15 DEKK-TEC Inc PIPELINE, H1 2018
3.16 DEVELOPMENT CENTER FOR BIOTECHNOLOGY PIPELINE, H1 2018
3.17 DONGGUAN HEC TAIGEN BIOPHARMACEUTICALS PIPELINE, H1 2018
3.18 HEC PHARM CO LTD PIPELINE, H1 2018
3.19 F. HOFFMANN-LA ROCHE LTD PIPELINE, H1 2018
3.20 FORTUNEROCK (CHINA)CO., LTD PIPELINE, H1 2018
3.21 GALACTICA BIOTECH LIMITED PIPELINE, H1 2018
3.22 GILEAD SCIENCES, INC PIPELINE, H1 2018
3.23 SPRING BANK PHARMACEUTICALS, INC. PIPELINE, H1 2018
3.24 GINKGOPHARMA CO. LTD PIPELINE, H1 2018
3.25 GLAXOSMITHKLINE PHARMACEUTICALS LTD PIPELINE, H1 2018
3.26 REGULUS THERAPEUTICS INC PIPELINE, H1 2018
3.27 ADAPTIMMUNE THERAPEUTICS PLC PIPELINE, H1 2018
3.28 OKAIROS AG PIPELINE, H1 2018
3.29 IMMUNEMED, INC PIPELINE, H1 2018
3.30 INOVIO PHARMACEUTICALS INC PIPELINE, H1 2018
3.31 INTEGRATED BIOTHERAPEUTICS INC PIPELINE, H1 2018
3.32 IQUR LTD. PIPELINE, H1 2018
3.33 JN-INTERNATIONAL MEDICAL CORPORATION PIPELINE, H1 2018
3.34 ALIOS BIOPHARMA INC PIPELINE, H1 2018
3.35 ACHILLION PHARMACEUTICALS, INC.- PIPELINE, H1 2018
3.36 KARYOPHARM THERAPEUTICS INC PIPELINE, H1 2018
3.37 LIFEARC PIPELINE, H1 2018
3.38 LIGAND PHARMACEUTICALS INC PIPELINE, H1 2018
3.39 MEDIVIR AB PIPELINE, H1 2018
3.40 MERCK & COMPANY, INC PIPELINE, H1 2018
3.41 METALLOPHARM, LLC PIPELINE, H1 2018
3.42 MICROBIO CO., LTD PIPELINE, H1 2018
3.43 MULTICELL TECHNOLOGIES INC PIPELINE, H1 2018
3.44 MULTICELL TECHNOLOGIES INC PIPELINE, H1 2018
3.45 NOVALEX THERAPEUTICS INC PIPELINE, H1 2018
3.46 NOVATARG THERAPEUTICS, INC PIPELINE, H1 2018
3.47 NOVATARG THERAPEUTICS, INC PIPELINE, H1 2018
3.48 PRESIDIO PHARMACEUTICALS, INC. PIPELINE, H1 2018
3.49 RIBOSCIENCE LLC PIPELINE, H1 2018
3.50 RODOS BIOTARGET GMBH PIPELINE, H1 2018
3.51 SAVOY PHARMACEUTICALS, INC PIPELINE, H1 2018
3.52 SOMAGENICS INC PIPELINE, H1 2018
3.53 TAIGEN BIOTECHNOLOGY CO., LTD PIPELINE, H1 2018
3.54 THERAPURE BIOPHARMA, INC PIPELINE, H1 2018
3.55 THEVAX GENETICS VACCINE CO LTD PIPELINE, H1 2018
3.56 TREK THERAPEUTICS, PBC PIPELINE, H1 2018
3.57 VAKZINE PROJEKT MANAGEMENT GMBH PIPELINE, H1 2018
3.58 WHANIN PHARM CO.,LTD PIPELINE, H1 2018
3.59 TGV-LABORATORIES PIPELINE, H1 2018

4 Hepatitis C Drug Snapshots
4.1 E1-E2-NS5A VACCINE DETAILS
4.1.1 Snapshot
4.1.2 Drug Overview
4.1.3 Mechanism of Action
4.1.4 Current Status
4.2 AV4025 DRUG DETAILS
4.2.1 Snapshot
4.2.2 Drug Overview
4.2.3 Mechanism of Action
4.2.4 Current Status
4.3 AVR560 DRUG DETAILS
4.3.1 Snapshot
4.3.2 Drug Overview
4.3.3 Mechanism of Action
4.3.4 Current Status
4.4 AMARNA VIRAL HEPATITIS DRUG DETAILS
4.4.1 Snapshot
4.4.2 Drug Overview
4.4.3 Mechanism of Action
4.4.4 Current Status
4.5 ARABS-3 DRUG DETAILS
4.5.1 Snapshot
4.5.2 Drug Overview
4.5.3 Mechanism of Action
4.5.4 Current Status
4.6 ARABS-4 DRUG DETAILS
4.6.1 Snapshot
4.6.2 Drug Overview
4.6.3 Mechanism of Action
4.6.4 Current Status
4.7 ARABS-5 DRUG DETAILS
4.7.1 Snapshot
4.7.2 Drug Overview
4.7.3 Mechanism of Action
4.7.4 Current Status
4.8 RAVIDASVIR DRUG DETAILS
4.8.1 Snapshot
4.8.2 Drug Overview
4.8.3 Mechanism of Action
4.8.4 Current Status
4.8.5 Trial Details
4.9 DANOPREVIR DRUG DETAILS
4.9.1 Snapshot
4.9.2 Drug Overview
4.9.3 Mechanism of Action
4.9.4 Current Status
4.10 AT-527 DRUG DETAILS
4.10.1 Snapshot
4.10.2 Drug Overview
4.10.3 Mechanism of Action
4.10.4 Current Status
4.10.5 Trial Details
4.11 PEG-IFN-SA DRUG DETAILS
4.11.1 Snapshot
4.11.2 Drug Overview
4.11.3 Mechanism of Action
4.11.4 Current Status
4.12 KW 2 DRUG DETAILS
4.12.1 Snapshot
4.12.2 Drug Overview
4.12.3 Mechanism of Action
4.12.4 Current Status
4.13 KW 5 DRUG DETAILS
4.13.1 Snapshot
4.13.2 Drug Overview
4.13.3 Mechanism of Action
4.13.4 Current Status
4.14 NS5A INHIBITOR (Beta Pharma) DRUG DETAILS
4.14.1 Snapshot
4.14.2 Drug Overview
4.14.3 Mechanism of Action
4.14.4 Current Status
4.15 NS5B INHIBITOR (Biocad CJSC) DRUG DETAILS
4.15.1 Snapshot
4.15.2 Drug Overview
4.15.3 Mechanism of Action
4.15.4 Current Status
4.16 NS3 PROTEASE INHIBITOR (Biocad) DRUG DETAILS
4.16.1 Snapshot
4.16.2 Drug Overview
4.16.3 Mechanism of Action
4.16.4 Current Status
4.17 NS5A INHIBITOR (Biocad) DRUG DETAILS
4.17.1 Snapshot
4.17.2 Drug Overview
4.17.3 Mechanism of Action
4.17.4 Current Status
4.18 BIT 225 DRUG DETAILS
4.18.1 Snapshot
4.18.2 Drug Overview
4.18.3 Mechanism of Action
4.18.4 Current Status
4.19 BIT314 DRUG DETAILS
4.19.1 Snapshot
4.19.2 Drug Overview
4.19.3 Mechanism of Action
4.19.4 Current Status
4.20 BBT-012 DRUG DETAILS
4.20.1 Snapshot
4.20.2 Drug Overview
4.20.3 Mechanism of Action
4.20.4 Current Status
4.21 HCV VACCINE (ARTES/Burnet) DRUG DETAILS
4.21.1 Snapshot
4.21.2 Drug Overview
4.21.3 Mechanism of Action
4.21.4 Current Status
4.22 CC-31244 DRUG DETAILS
4.22.1 Snapshot
4.22.2 Drug Overview
4.22.3 Mechanism of Action
4.22.4 Current Status
4.23 CC-2850 DRUG DETAILS
4.23.1 Snapshot
4.23.2 Drug Overview
4.23.3 Mechanism of Action
4.23.4 Current Status
4.24 CC-2069 DRUG DETAILS
4.24.1 Snapshot
4.24.2 Drug Overview
4.24.3 Mechanism of Action
4.24.4 Current Status
4.25 EMRICASAN DRUG DETAILS
4.25.1 Snapshot
4.25.2 Drug Overview
4.25.3 Mechanism of Action
4.25.4 Current Status
4.26 IFN-Y FUSION PROTEINS DETAILS
4.26.1 Snapshot
4.26.2 Drug Overview
4.26.3 Mechanism of Action
4.26.4 Current Status
4.27 DCB-F1 DRUG DETAILS
4.27.1 Snapshot
4.27.2 Drug Overview
4.27.3 Mechanism of Action
4.27.4 Current Status
4.28 FURAPREVIR DRUG DETAILS
4.28.1 Snapshot
4.28.2 Drug Overview
4.28.3 Mechanism of Action
4.28.4 Current Status
4.29 YIMITASVIR DRUG DETAILS
4.29.1 Snapshot
4.29.2 Drug Overview
4.29.3 Mechanism of Action
4.29.4 Current Status
4.30 RITONAVIR-BOOSTED DANOPREVIR DRUG DETAILS
4.30.1 Snapshot
4.30.2 Drug Overview
4.30.3 Mechanism of Action
4.30.4 Current Status
4.31 MIRAVIRSEN DRUG DETAILS
4.31.1 Snapshot
4.31.2 Drug Overview
4.31.3 Mechanism of Action
4.31.4 Current Status
4.32 rHSA/IFNα2a DRUG DETAILS
4.32.1 Snapshot
4.32.2 Drug Overview
4.32.3 Mechanism of Action
4.32.4 Current Status
4.33 rHSA/IFNα2b DRUG DETAILS
4.33.1 Snapshot
4.33.2 Drug Overview
4.33.3 Mechanism of Action
4.33.4 Current Status
4.34 Small molecule for HCV (Galactica) DRUG DETAILS
4.34.1 Snapshot
4.34.2 Drug Overview
4.34.3 Mechanism of Action
4.34.4 Current Status
4.35 GS-9669 DRUG DETAILS
4.35.1 Snapshot
4.35.2 Drug Overview
4.35.3 Mechanism of Action
4.35.4 Current Status
4.36 GS-9857 DRUG DETAILS
4.36.1 Snapshot
4.36.2 Drug Overview
4.36.3 Mechanism of Action
4.36.4 Current Status
4.37 INARIGIVIR DRUG DETAILS
4.37.1 Snapshot
4.37.2 Drug Overview
4.37.3 Mechanism of Action
4.37.4 Current Status
4.38 NS3/4A INHIBITOR + NS5B INHIBITOR (GINKGO) DRUG DETAILS
4.38.1 Snapshot
4.38.2 Drug Overview
4.38.3 Mechanism of Action
4.38.4 Current Status
4.39 NS3/4A inhibitor + NS5A inhibitor (Ginkgo)DRUG DETAILS
4.39.1 Snapshot
4.39.2 Drug Overview
4.39.3 Mechanism of Action
4.39.4 Current Status
4.40 NS3/4A inhibitor + NS5B inhibitor + NS5A inhibitor (Ginkgo)DRUG DETAILS
4.40.1 Snapshot
4.40.2 Drug Overview
4.40.3 Mechanism of Action
4.40.4 Current Status
4.41 Seraprevir DRUG DETAILS
4.41.1 Snapshot
4.41.2 Drug Overview
4.41.3 Mechanism of Action
4.41.4 Current Status
4.42 GSK 2878175 DRUG DETAILS
4.42.1 Snapshot
4.42.2 Drug Overview
4.42.3 Mechanism of Action
4.42.4 Current Status
4.43 Hepatitis C+ Vaccine DRUG DETAILS
4.43.1 Snapshot
4.43.2 Drug Overview
4.43.3 Mechanism of Action
4.44 GSK2336805 DRUG DETAILS
4.44.1 Snapshot
4.44.2 Drug Overview
4.44.3 Mechanism of Action
4.44.4 Current Status
4.45 miR122 DRUG DETAILS
4.45.1 Snapshot
4.45.2 Drug Overview
4.45.3 Mechanism of Action
4.45.4 Current Status
4.46 AUTOLOGOUS T-cell THERAPIES DRUG DETAILS
4.46.1 Snapshot
4.46.2 Drug Overview
4.46.3 Mechanism of Action
4.46.4 Current Status
4.47 T CELL HCV VACCINE DETAILS
4.47.1 Snapshot
4.47.2 Drug Overview
4.47.3 Mechanism of Action
4.47.4 Current Status
4.48 Recombinant VSF DETAILS
4.48.1 Snapshot
4.48.2 Drug Overview
4.48.3 Mechanism of Action
4.48.4 Current Status
4.49 INO8000 DRUG DETAILS
4.49.1 Snapshot
4.49.2 Drug Overview
4.49.3 Mechanism of Action
4.49.4 Current Status
4.50 Hepatitis C Antibodies (Integrated Bio) DRUG DETAILS
4.50.1 Snapshot
4.50.2 Drug Overview
4.50.3 Mechanism of Action
4.50.4 Current Status
4.51 Hepatitis C vaccine (iQur) DRUG DETAILS
4.51.1 Snapshot
4.51.2 Drug Overview
4.51.3 Mechanism of Action
4.51.4 Current Status
4.52 Hepatitis C vaccine (JNIMC) DRUG DETAILS
4.52.1 Snapshot
4.52.2 Drug Overview
4.52.3 Mechanism of Action
4.52.4 Current Status
4.53 AL-335 DRUG DETAILS
4.53.1 Snapshot
4.53.2 Drug Overview
4.53.3 Mechanism of Action
4.53.4 Current Status
4.54 AL-516 DRUG DETAILS
4.54.1 Snapshot
4.54.2 Drug Overview
4.54.3 Mechanism of Action
4.54.4 Current Status
4.55 ACH-3102 DRUG DETAILS
4.55.1 Snapshot
4.55.2 Drug Overview
4.55.3 Mechanism of Action
4.55.4 Current Status
4.56 ACH-3422 DRUG DETAILS
4.56.1 Snapshot
4.56.2 Drug Overview
4.56.3 Mechanism of Action
4.56.4 Current Status
4.57 ACH-1625 DRUG DETAILS
4.57.1 Snapshot
4.57.2 Drug Overview
4.57.3 Mechanism of Action
4.57.4 Current Status
4.58 VERDINEXOR DRUG DETAILS
4.58.1 Snapshot
4.58.2 Drug Overview
4.58.3 Mechanism of Action
4.58.4 Current Status
4.59 HEPATITIS C ANTIBODY (LIFEARC) DRUG DETAILS
4.59.1 Snapshot
4.59.2 Drug Overview
4.59.3 Mechanism of Action
4.59.4 Current Status
4.60 NUC-101DRUG DETAILS
4.60.1 Snapshot
4.60.2 Drug Overview
4.60.3 Mechanism of Action
4.60.4 Current Status
4.61 MIV-802 DRUG DETAILS
4.61.1 Snapshot
4.61.2 Drug Overview
4.61.3 Mechanism of Action
4.61.4 Current Status
4.62 MBX 700 DRUG DETAILS
4.62.1 Snapshot
4.62.2 Drug Overview
4.62.3 Mechanism of Action
4.62.4 Current Status
4.63 Hepatitis C virus therapeutics (MetalloPharm) DRUG DETAILS
4.63.1 Snapshot
4.63.2 Drug Overview
4.63.3 Mechanism of Action
4.63.4 Current Status
4.64 MB-110 DRUG DETAILS
4.64.1 Snapshot
4.64.2 Drug Overview
4.64.3 Mechanism of Action
4.64.4 Current Status
4.65 MCT-465 DRUG DETAILS
4.65.1 Snapshot
4.65.2 Drug Overview
4.65.3 Mechanism of Action
4.65.4 Current Status
4.66 MCT-475 DRUG DETAILS
4.66.1 Snapshot
4.66.2 Drug Overview
4.66.3 Mechanism of Action
4.66.4 Current Status
4.67 Peglamda DRUG DETAILS
4.67.1 Snapshot
4.67.2 Drug Overview
4.67.3 Mechanism of Action
4.67.4 Current Status
4.68 Interferon alpha 2b biosimilar DRUG DETAILS
4.68.1 Snapshot
4.68.2 Drug Overview
4.68.3 Mechanism of Action
4.68.4 Current Status
4.69 HCV NS3/4A protease inhibitor (Novalex) DRUG DETAILS
4.69.1 Snapshot
4.69.2 Drug Overview
4.69.3 Mechanism of Action
4.69.4 Current Status
4.70 AMPK activators for hcv DRUG DETAILS
4.70.1 Snapshot
4.70.2 Drug Overview
4.70.3 Mechanism of Action
4.70.4 Current Status
4.71 Ropeginterferon alfa 2b DRUG DETAILS
4.71.1 Snapshot
4.71.2 Drug Overview
4.71.3 Mechanism of Action
4.71.4 Current Status
4.72 PPI 383 DRUG DETAILS
4.72.1 Snapshot
4.72.2 Drug Overview
4.72.3 Mechanism of Action
4.72.4 Current Status
4.73 Ravidasvir Hydrochloride DRUG DETAILS
4.73.1 Snapshot
4.73.2 Drug Overview
4.73.3 Mechanism of Action
4.73.4 Current Status
4.74 RBS-1154 and RBS 1049 DRUG DETAILS
4.74.1 Snapshot
4.74.2 Drug Overview
4.74.3 Mechanism of Action
4.74.4 Current Status
4.75 RBT05 DRUG DETAILS
4.75.1 Snapshot
4.75.2 Drug Overview
4.75.3 Mechanism of Action
4.75.4 Current Status
4.76 Viroprev DRUG DETAILS
4.76.1 Snapshot
4.76.2 Drug Overview
4.76.3 Mechanism of Action
4.76.4 Current Status
4.77 RNAi therapeutics DETAILS
4.77.1 Snapshot
4.77.2 Drug Overview
4.77.3 Mechanism of Action
4.77.4 Current Status
4.78 TG-2349 DRUG DETAILS
4.78.1 Snapshot
4.78.2 Drug Overview
4.78.3 Mechanism of Action
4.78.4 Current Status
4.79 JKB 122 DRUG DETAILS
4.79.1 Snapshot
4.79.2 Drug Overview
4.79.3 Mechanism of Action
4.79.4 Current Status
4.80 TBI 301 DRUG DETAILS
4.80.1 Snapshot
4.80.2 Drug Overview
4.80.3 Mechanism of Action
4.80.4 Current Status
4.81 TVGV-HC DRUG DETAILS
4.81.1 Snapshot
4.81.2 Drug Overview
4.81.3 Mechanism of Action
4.81.4 Current Status
4.82 TD-6450 DRUG DETAILS
4.82.1 Snapshot
4.82.2 Drug Overview
4.82.3 Mechanism of Action
4.82.4 Current Status
4.83 Soluferon DRUG DETAILS
4.83.1 Snapshot
4.83.2 Drug Overview
4.83.3 Mechanism of Action
4.83.4 Current Status
4.84 HCV (WhanIn) DRUG DETAILS
4.84.1 Snapshot
4.84.2 Drug Overview
4.84.3 Mechanism of Action
4.84.4 Current Status
4.85 Hep-1732 DRUG DETAILS
4.85.1 Snapshot
4.85.2 Drug Overview
4.85.3 Mechanism of Action
4.85.4 Current Status

5 Recent Developments in Hepatitis C Pipeline
5.1 DAAs considered potential against HCV in older citizens
5.2 Egypt focusing on eliminating HCV from the country
5.3 New mathematical model analyzes HCV development in detail

6 Appendix
6.1 ABOUT VPA RESEARCH
6.2 SOURCES AND RESEARCH METHODOLOGY

1.1 LIST OF FIGURES
Figure 1: Hepatitis C Pipeline by Phase, H1- 2018
Figure 2: Hepatitis C Pipeline by Companies, H1- 2018
Figure 3: Company wise Pipeline Drug Phases, H1- 2018
Figure 4: Hepatitis C Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism wise Pipeline Drug Phases, H1- 2018

1.2 LIST OF TABLES
Table 1: Hepatitis C Pipeline by Phase, H1- 2018
Table 2: Hepatitis C Pipeline by Companies, H1- 2018
Table 3: Hepatitis C Pipeline by Mechanism of Action, H1- 2018
Table 4: Akshaya Bio Inc.- Hepatitis C Pipeline, H1- 2018
Table 5: AllaChem, LLC - Hepatitis C Pipeline, H1- 2018
Table 6: Amarna Therapeutics BV - Hepatitis C Pipeline, H1- 2018
Table 7: ARA Healthcare Pvt Ltd - Hepatitis C Pipeline, H1- 2018
Table 8: Ascletis, Inc - Hepatitis C Pipeline, H1- 2018
Table 9: Atea Pharmaceuticals, Inc - Hepatitis C Pipeline, H1- 2018
Table 10: Beijing Kawin Technology Share-Holding Co., Ltd.- Hepatitis C Pipeline, H1- 2018
Table 11: Beta Pharma, Inc.- Hepatitis C Pipeline, H1- 2018
Table 12: Biocad CJSC - Hepatitis C Pipeline, H1- 2018
Table 13: Biotron Limited - Hepatitis C Pipeline, H1- 2018
Table 14: Bolder BioTechnology, Inc - Hepatitis C Pipeline, H1- 2018
Table 15: ARTES Biotechnology GmbH - Hepatitis C Pipeline, H1- 2018
Table 16: Cocrystal Pharma Inc - Hepatitis C Pipeline, H1- 2018
Table 17: Conatus Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 18: DEKK-TEC Inc - Hepatitis C Pipeline, H1- 2018
Table 19: Development Center for Biotechnology - Hepatitis C Pipeline, H1- 2018
Table 20: Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd - Hepatitis C Pipeline, H1- 2018
Table 21: HEC Pharm Co Ltd - Hepatitis C Pipeline, H1- 2018
Table 22: F. Hoffmann-La Roche Ltd - Hepatitis C Pipeline, H1- 2018
Table 23: FortuneRock(China)Co., Ltd.- Hepatitis C Pipeline, H1- 2018
Table 24: Galactica Biotech Limited - Hepatitis C Pipeline, H1- 2018
Table 25: Gilead Sciences, Inc.- Hepatitis C Pipeline, H1- 2018
Table 26: Spring Bank Pharmaceuticals, Inc.- Hepatitis C Pipeline, H1- 2018
Table 27: GinkgoPharma Co. Ltd - Hepatitis C Pipeline, H1- 2018
Table 28: GlaxoSmithKline Pharmaceuticals Ltd - Hepatitis C Pipeline, H1- 2018
Table 29: Regulus Therapeutics Inc - Hepatitis C Pipeline, H1- 2018
Table 30: Adaptimmune Therapeutics plc - Hepatitis C Pipeline, H1- 2018
Table 31: Okairos AG - Hepatitis C Pipeline, H1- 2018
Table 32: ImmuneMed, Inc. - Hepatitis C Pipeline, H1- 2018
Table 33: Inovio Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 34: Integrated Biotherapeutics Inc.- Hepatitis C Pipeline, H1- 2018
Table 35: iQur Ltd.- Hepatitis C Pipeline, H1- 2018
Table 36: JN-International Medical Corporation - Hepatitis C Pipeline, H1- 2018
Table 37: Alios BioPharma Inc.- Hepatitis C Pipeline, H1- 2018
Table 38: Achillion Pharmaceuticals, Inc.- Hepatitis C Pipeline, H1- 2018
Table 39: Karyopharm Therapeutics Inc - Hepatitis C Pipeline, H1- 2018
Table 40: LifeArc - Hepatitis C Pipeline, H1- 2018
Table 41: Ligand Pharmaceuticals Inc - Hepatitis C Pipeline, H1- 2018
Table 42: Medivir AB - Hepatitis C Pipeline, H1- 2018
Table 43: Merck & Company, Inc.- Hepatitis C Pipeline, H1- 2018
Table 44: Metallopharm, LLC - Hepatitis C Pipeline, H1- 2018
Table 45: Microbio Co., Ltd. Hepatitis C Pipeline, H1- 2018
Table 46: MultiCell Technologies Inc Hepatitis C Pipeline, H1- 2018
Table 47: MultiCell Technologies Inc Hepatitis C Pipeline, H1- 2018
Table 48: Novalex Therapeutics Inc Hepatitis C Pipeline, H1- 2018
Table 49: NovaTarg Therapeutics, Inc Hepatitis C Pipeline, H1- 2018
Table 50: NovaTarg Therapeutics, Inc Hepatitis C Pipeline, H1- 2018
Table 51: Presidio Pharmaceuticals, Inc. Hepatitis C Pipeline, H1- 2018
Table 52: Riboscience LLC Hepatitis C Pipeline, H1- 2018
Table 53: Rodos BioTarget GmbH Hepatitis C Pipeline, H1- 2018
Table 54: Savoy Pharmaceuticals, Inc Hepatitis C Pipeline, H1- 2018
Table 55: SomaGenics Inc Hepatitis C Pipeline, H1- 2018
Table 56: TaiGen Biotechnology Co., Ltd. Hepatitis C Pipeline, H1- 2018
Table 57: Therapure BioPharma, Inc Hepatitis C Pipeline, H1- 2018
Table 58: Thevax Genetics Vaccine Co Ltd Hepatitis C Pipeline, H1- 2018
Table 59: Trek Therapeutics, PBC Hepatitis C Pipeline, H1- 2018
Table 60: Vakzine Projekt Management GmbH Hepatitis C Pipeline, H1- 2018
Table 61: WHANIN PHARM CO.,LTD Hepatitis C Pipeline, H1- 2018
Table 62: TGV-Laboratories Hepatitis C Pipeline, H1- 2018

発刊日

2018/06/27

体裁

PDF / 150ページ

販売価格

1,500USD

発行

VPA Research

備考

※ご請求は、お申込日のTTSレートで円換算し、消費税を加えた金額になります。
※販売価格はシングルユーザーライセンスのものとなります。他のライセンス形態・価格に関しましてはご相談下さい。
※本レポートは、英文です。PDF(電子媒体)での納品となります。
※本レポートは取り寄せとなりますので、申し込みからお届けまで、多少時間が掛かる場合がございます。

関連カテゴリ

疾病別治療・領域別治療

購入・お問い合わせ

このレポートを購入

詳細を問い合わせる


PAGE